Currently, there are 601.10M common shares owned by the public and among those 591.90M shares have been available to trade.
Insiders at the company have transacted a total of 181 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 78 of these insider trades were purchases, accounting for 1,244,741 shares. Insider sales of the common stock occurred on 103 occasions, with total insider shares sold totaling 1,109,623 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The company’s stock has a 5-day price change of 0.06% and 28.47% over the past three months. EW shares are trading 12.98% year to date (YTD), with the 12-month market performance up to 11.05% higher. It has a 12-month low price of $60.57 and touched a high of $94.87 over the same period. EW has an average intraday trading volume of 4.33 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.73%, 9.77%, and 10.22% respectively.
Institutional ownership of Edwards Lifesciences Corp (NYSE: EW) shares accounts for 83.41% of the company’s 601.10M shares outstanding.
It has a market capitalization of $51.80B and a beta (3y monthly) value of 1.06. The stock’s trailing 12-month PE ratio is 37.43, while the earnings-per-share (ttm) stands at $2.30. The company has a PEG of 4.04 and a Quick Ratio of 2.40 with the debt-to-equity ratio at 0.10. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.81% over the week and 2.97% over the month.
Analysts forecast that Edwards Lifesciences Corp (EW) will achieve an EPS of $0.64 for the current quarter, $0.7 for the next quarter and $3.09 for 2025. The lowest estimate earnings-per-share for the quarter is $0.63 while analysts give the company a high EPS estimate of $0.66. Comparatively, EPS for the current quarter was $0.62 a year ago. Earnings per share for the fiscal year are expected to increase by 9.75%, and 12.38% over the next financial year. EPS should shrink at an annualized rate of 9.26% over the next five years, compared to 15.35% over the past 5-year period.
Looking at the support for the EW, a number of firms have released research notes about the stock. Wells Fargo stated their Overweight rating for the stock in a research note on February 02, 2024, with the firm’s price target at $94. Evercore ISI coverage for the Edwards Lifesciences Corp (EW) stock in a research note released on January 04, 2024 offered a In-line rating with a price target of $77. Citigroup was of a view on December 11, 2023 that the stock is Neutral, while Wolfe Research gave the stock Underperform rating on November 28, 2023, issuing a price target of $57. Oppenheimer on their part issued Outperform rating on September 26, 2023.
